Is a
Patent attributes
Patent Jurisdiction
Patent Number
Date of Patent
December 11, 2007
Patent Application Number
10308721
Date Filed
December 3, 2002
Patent Citations Received
Patent Primary Examiner
Patent abstract
Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
